(NYSE:ZTS) Zoetis Inc Sets 52 Week High Record Of $111.66

Zoetis Inc (NYSE:ZTS)

June 11th, 2019

Amidst falling markets Zoetis Inc fell ($0.06) Tuesday, a 0.05% drop, closing at $110.16. Despite the drop in price it hit a new 52 week high of $111.66.

ZTS outperformed the rest of the Healthcare sector which went down only -0.25% today.

Zoetis Inc is listed on the S&P 500 index, and was one of 262 stocks that dropped today. Weighted by market cap, ZTS represents about 0.21% of the S&P 500.

Expectations from 15 analysts suggest that Zoetis Inc could rise somewhat (2.18%), while Finbox has calculated (with low uncertainty) a fair value price of $85.20.

Market Sectors

The market sectors were mixed Tuesday with a majority of the sectors trending up. Consumer Staples saw the biggest increase of the day (0.41%), while the Industrials sector saw the biggest drop (-0.90%). Information Technology has seen the biggest year-to-date gain of 23.75%.

Industrials and Utilities experienced turn-arounds from their five day positive performances with Industrials dropping -0.90%.

Sector Breakdown

  • Consumer Staples, up 0.41%.
  • Consumer Discretionary, up 0.33%.
  • Communication Services, up 0.29%.
  • Real Estate, up 0.18%.
  • Energy, up 0.12%.
  • Information Technology, up 0.02%.
  • Financials, stayed even 0.00%.
  • Materials, down -0.07%.
  • Healthcare, down -0.25%.
  • Utilities, down -0.69%.
  • Industrials, down -0.90%.

Zoetis Inc Info

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides medicated feed additives that offer medicines to livestock; and other pharmaceutical products, which comprise allergy and dermatology, pain and sedation, antiemetic, reproductive, and oncology products. In addition, the company offers portable blood and urine analysis systems, and point-of-care diagnostic products, including instruments and reagents, rapid immunoassay tests, reference laboratory kits, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in complementary areas, such as biodevices and genetics. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

All amounts in USD unless otherwise indicated

ZTS daily update
ZTS daily update

Via UnSplash

Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.

Tell us what you think